Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Welcome to our latest round up of key business of science stories from across Springer Nature’s portfolio of journals. This month we look at how biotech funding flourished during the pandemic, and explore the latest information regarding both AstraZeneca’s and Johnson & Johnson’s vaccines in the rollout against COVID-19.
Our monthly roundup of 'business of science' stories from across Springer Nature’s portfolio of journals explores the relationships between academia, startups and big pharma, as well as following the progress of the COVID-19 vaccine rollout.
A surge of efforts focused on the drug target B cell maturation antigen could transform the treatment of multiple myeloma and help to establish the relative merits and optimization strategies for emerging treatment modalities with wider applications.
After a slow start due to the COVID-19 pandemic, oncology dealmaking thrived in 2020 as immuno-oncology fueled a number of high-value drug licensing deals and a string of billion-dollar M&As were announced.
Our monthly round up of key biopharma business stories from across Springer Nature’s portfolio of journals, including the latest on COVID-19 vaccines and a focus on oncology.
In our first monthly round up of the year we explore the big stories from 2020, including key biopharma deals, FDA approvals and IPOs, as well as the extraordinary impact of COVID-19 on science throughout an unusual 12 months.
